Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058871 | 0.88 | POLB (0.39) | RXFP1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL19187939 | 0.85 | NPSR1 (0.37) | RXFP1KMT2AL3MBTL1KDM4ENPC1 | |
| SCHEMBL3063932 | 0.81 | ALDH1A1 (0.37) | RXFP1L3MBTL1KDM4EALDH1A1GABRA2 | |
| SCHEMBL1583259 | 0.81 | KMT2A (0.42) | RXFP1KMT2AKDM4EPKMMAPT | |
| SCHEMBL3690164 | 0.81 | ALDH1A1 (0.47) | KMT2AL3MBTL1KDM4EALDH1A1PKM | |
| SCHEMBL1583734 | 0.79 | MAPT (0.37) | RXFP1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL1583217 | 0.77 | KDM4E (0.46) | L3MBTL1KDM4EALDH1A1GABRA2GABRB2 | |
| SCHEMBL13090307 | 0.76 | POLB (0.40) | RXFP1L3MBTL1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL1583803 | 0.76 | NOTUM (0.36) | RXFP1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL1583417 | 0.76 | RXFP1 (0.36) | RXFP1KMT2AKDM4EPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | RXFP1 4014/4885KMT2A 4584/4885L3MBTL1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.